Mucocutaneous adverse events to immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Since the approval of ipilimumab in 2011, a total of nine ICIs have gained indications for various solid and hematologic malignancies. The expanding use of ICIs in oncology underscores the need for diagnosis and treatment expert...

Descripción completa

Detalles Bibliográficos
Autores principales: Muhaj, Fiorinda, Karri, Padmavathi V., Moody, Wylie, Brown, Alexandria, Patel, Anisha B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Allergy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017442/
https://www.ncbi.nlm.nih.gov/pubmed/36938327
http://dx.doi.org/10.3389/falgy.2023.1147513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017442/
https://www.ncbi.nlm.nih.gov/pubmed/36938327
http://dx.doi.org/10.3389/falgy.2023.1147513

Ejemplares similares